A phase I study of niraparib in combination with temozolomide (TMZ) in patients with advanced cancer. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This abstract does not ...
Repotrectinib achieved a high objective response rate and durable response in the pivotal TRIDENT-1 trial. Repotrectinib is an orally administered tyrosine kinase inhibitor (TKI) that targets ROS1 ...
Nuvation Bio's Taletrectinib shows promising data in phase 2 trials for ROS1-positive NSCLC, outperforming current market leaders in key metrics like DOR and PFS. Despite a small target market, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback